权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Small Molecule Selective HDAC3 Inhibitors as a Novel Therapy for PTSD

小分子选择性 HDAC3 抑制剂作为 PTSD 的新疗法

基本信息

批准号：
9141690
负责人：
Edward Holson
金额：
$ 37.97万
依托单位：
KDAC THERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-03-21 至 2018-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9141690
关键词：
Acetylation Adopted Affect American Animal Model Attenuated BDNF gene Back Behavior Behavior Therapy Behavioral Benchmarking Biological Biological Assay Brain Brain region Chronic Post Traumatic Stress Disorder Clinical Clinical Treatment Cognitive Therapy Comorbidity Coupled Data Development Disease Dose Dose-Limiting Drug Addiction Drug abuse Epigenetic Process Evaluation Extinction (Psychology)FDA approved Fright Gene Expression Gene Targeting Generations Genetic Goals HDAC1 gene HDAC3 gene Hand Health Hippocampus (Brain)Histones In Vitro Individual Lead Learning Learning Disorders Location Long-Term Potentiation Lysine Measures Memory Memory Disorders Modeling Mus Neurobiology Neurons Pathway interactions Patients Pharmaceutical Preparations Pharmacotherapy Phase Pilot Projects Post-Traumatic Stress Disorders Property Protein Isoforms Quality of life Rattus Research Resistance Risk Rodent Model Role Safety Slice Small Business Innovation Research Grant Societies Sodium Butyrate Stress Surrogate Markers Synaptic Receptors Synaptic plasticity Testing Therapeutic Therapeutic Index Toxic effect Translating Translations Treatment Efficacy Valproic Acid Vorinostat base clinical application conditioned fear design disorder later incidence prevention drug seeking behavior effective therapy fear memory improved in vivo inhibitor/antagonist lead series learning extinction long term memory minimal risk mouse model neuronal circuitry novel novel therapeutics pre-clinical productivity loss public health relevance reflex disorder response small molecule small molecule therapeutics success trend

项目摘要

DESCRIPTION (provided by applicant): Post-traumatic stress disorder (PTSD) is a major health problem, affecting over 5 million Americans every year. Despite advances in behavioral treatment approaches (e.g., prolonged exposure therapy (PE, a form of cognitive behavioral therapy (CBT)) and the more recently adopted paradigm of combining PE/CBT with medications to augment fear extinction learning, these pharmacotherapeutic approaches have had mixed success, and there is an urgent need for a broader array of effective medications for chronic PTSD. With the emerging understanding of PTSD as a learning and memory disorder generally, and a fear reflex disorder specifically, the opportunity to develop novel pharmacotherapeutics targeting mechanisms of fear extinction to expand beyond the current drugs that act at the level of synaptic receptors, has exciting potential. An increasing body of work has shown that epigenetic effects driven by nonspecific HDAC inhibitors (such as SAHA (Vorinostat), valproic acid (VPA) or sodium butyrate (NaB)) can facilitate and enhance fear extinction in multiple rodent models. The problem is that all FDA-approved and current pre-clinical HDAC inhibitors are (a) not sufficiently isoform selective (inhibiting many of the 11 HDAC isoforms), (b) not safe for non-oncological application (toxicity driven by both HDAC1/2 inhibition and off-target effects) and (c) have poor CNS drug-like properties. Highly isoform-selective HDAC inhibitors are needed to mitigate these risks and increase the therapeutic window. We believe HDAC3 is the best target, as (i) genetic or pharmacological inhibition of HDAC3 persistently enhances long-term memory, (ii) an HDAC1/2/3-selective inhibitor (CI-994) increased synaptic plasticity, attenuated remote fear memories, and enhanced extinction in a classic mouse model of fear conditioning; (iii) HDAC3 has the least homology to HDACs1 and 2, offering unique and distinctive rational design approaches towards high isoform selectivity; and (iv) KDAc Therapeutics' HDAC3-selective inhibitors have demonstrated improved safety and tolerability, mitigating known dose-limiting toxicities driven by HDAC1/2 inhibition. Our lead development candidate, KDAC0001, a novel highly optimized HDAC3-selective inhibitor, has been extensively characterized in vitro and in vivo, with a preliminary pre-clinical ADME/PK/ toxicological profile, good CNS drug properties and initial efficacy in learning and memory paradigms. Thus, with selective inhibitors in hand, we can enable a focused evaluation of the hypothesis that HDAC3-selective inhibition will be safe and effective in enhancing extinction (rate and persistence) in fear conditioning models. These proposed Phase I SBIR studies will not only test these molecules for application, and potential clinical translation, to PTSD, but wil also provide the first assessment of this mechanism (HDAC3 inhibition) in enhancing fear extinction with highly HDAC3-selective inhibitors. Our long-term goal is to develop an HDAC3- selective inhibitor as a novel small molecule therapeutic that would augment PE or CBT to enhance extinction learning in PTSD and promote persistent fear inhibition.